Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Medicines shortages

EU council members suggest relocating drugs manufacturing processes to Europe

Members of the Council of the European Union have debated whether relocating medicines production back to the EU would mitigate medicines shortages.

A paper summarising the outcome of the debate, which was held on 9 and 10 December 2019, said member states “supported the idea to develop and implement an EU work agenda on pharmaceutical policy to avoid medicines shortages across the union”.

It added that several measures were discussed to mitigate shortages, including “encouraging the relocation of medicines production back to the EU”.

The debate was called by the General Secretariat of the Council (GSC) in November 2019, which noted the prevention of shortages as “crucial for the continuity of care”.

The letter said shortages were partly the result of a “longer, more complex and fragmented” supply chain “as companies have located a large part of production of medicines outside the EU”.

The GSC, therefore, called a policy debate to discuss whether there is a need for “EU legislative measures to require back-up manufacturing capacity, earlier notification of interruptions and stronger measures to ensure continuity of supply”.

The suggestion to move medicines manufacturing back to the EU follows a call from generics manufacturers on the European Commission to encourage this to help stabilise the medicines supply chain.

The debate also proposed “transferring medicines from one member state to another with some exemptions”, “exchanging information on stocks” and “intensifying market surveillance” to tackle the ongoing problem of medicines shortages.

The Council of the European Union works with the European Parliament to negotiate and adopt legislative acts.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20207458

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons is the definitive reference source of analytical data for drugs and poisons.

    £535.00Buy now
  • Injectable Drugs Guide

    Injectable Drugs Guide

    A user friendly, single point of reference for healthcare professionals in the safe and effective administration of injectable medicines.

    £54.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.